Loading...
After oral ingestion, the glucocorticoid budesonide is nearly 90 percent metabolized in its first pass through the liver. Its slow-release form has topical activity against Crohn's disease with fewer systemic side effects than other steroids (see JW Nov 1 1994, p. 65, accession number 941012001, or N Eng J Med 1994; 331:842, 836, 873). In this 16-week, randomized multinational trial, supported by the maker of budesonide, 182 patients with mild-to-moderately active Crohn's disease of the terminal ileum, ascending colon, or both received either controlled-release budesonide (9 mg daily) or slow-release mesalamine (2 grams twice daily). Mesalamine, the salicylic acid portion of sulfasalazine, is also frequently used to treat Crohn's disease.
Th…